Abstract
Perinatal asphyxia (PA) still constitutes a common complication involving a large number of infants with or without congenital heart diseases (CHD). PA affects 0.2-0.6% of full-term neonates, 20% of which suffer mortal hypoxic-ischemic encephalopathy, and among survivors 25% exhibit permanent consequences at neuropsychological level. Each year, about one third of 1000 live births underwent to surgical intervention in early infancy and/or are at risk for ominous outcome. Advances in brain monitoring, in anesthetic and cardiothoracic surgical techniques, including selective or total body cooling, cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest, have essentially reduced mortality expanding the possibility to address functional neurologic and cardiac outcomes in long-term survivors. However, open-heart surgery constitutes a time-frame of planned ischemia-reperfusion injury, which is a price to pay in the treatment or palliation of CHD. Infants who underwent heart surgery and non-CHD infants complicated by PA share similarities in their neurodevelopmental profile and a common form of brain damage due to hypoxic–ischemic injury.
The purpose of the present review was to evaluate different mechanisms implicated in brain injury following CPB and PA and how it is possible to monitor such injury by means of available biomarkers (S100B protein, Activin A, Adrenomedullin).
Keywords: Activin A, adrenomedullin, biomarkers, brain damage, cardiac disease, congenital disease, CPB, S100B.
CNS & Neurological Disorders - Drug Targets
Title:Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
Volume: 14 Issue: 1
Author(s): Raul Abella, Alessandro Varrica, Angela Satriano, Guido Tettamanti, Gabriele Pelissero, Antonio D.W. Gavilanes, Luc J. Zimmermann, Hans J. Vles, Maria C. Strozzi, Francesca R. Pluchinotta and Diego Gazzolo
Affiliation:
Keywords: Activin A, adrenomedullin, biomarkers, brain damage, cardiac disease, congenital disease, CPB, S100B.
Abstract: Perinatal asphyxia (PA) still constitutes a common complication involving a large number of infants with or without congenital heart diseases (CHD). PA affects 0.2-0.6% of full-term neonates, 20% of which suffer mortal hypoxic-ischemic encephalopathy, and among survivors 25% exhibit permanent consequences at neuropsychological level. Each year, about one third of 1000 live births underwent to surgical intervention in early infancy and/or are at risk for ominous outcome. Advances in brain monitoring, in anesthetic and cardiothoracic surgical techniques, including selective or total body cooling, cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest, have essentially reduced mortality expanding the possibility to address functional neurologic and cardiac outcomes in long-term survivors. However, open-heart surgery constitutes a time-frame of planned ischemia-reperfusion injury, which is a price to pay in the treatment or palliation of CHD. Infants who underwent heart surgery and non-CHD infants complicated by PA share similarities in their neurodevelopmental profile and a common form of brain damage due to hypoxic–ischemic injury.
The purpose of the present review was to evaluate different mechanisms implicated in brain injury following CPB and PA and how it is possible to monitor such injury by means of available biomarkers (S100B protein, Activin A, Adrenomedullin).
Export Options
About this article
Cite this article as:
Abella Raul, Varrica Alessandro, Satriano Angela, Tettamanti Guido, Pelissero Gabriele, Gavilanes D.W. Antonio, Zimmermann J. Luc, Vles J. Hans, Strozzi C. Maria, Pluchinotta R. Francesca and Gazzolo Diego, Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases, CNS & Neurological Disorders - Drug Targets 2015; 14 (1) . https://dx.doi.org/10.2174/1871527314666150116114648
DOI https://dx.doi.org/10.2174/1871527314666150116114648 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Intimal Hyperplasia in Murine Models
Current Drug Targets Receptor-Based Computational Screening of Compound Databases: The Main Docking-Scoring Engines
Current Protein & Peptide Science Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Current Cardiology Reviews Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Cellular Therapy for Heart Failure
Current Cardiology Reviews Regulatory Mechanisms of Cardiac Development and Repair
Cardiovascular & Hematological Disorders-Drug Targets Chronic Heart Failure- Potential for Pharmacological Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting Platelet-Neutrophil Interactions in Giant-Cell Arteritis
Current Pharmaceutical Design Autologous Cell Therapy for Vascular Regeneration: The Role of Proangiogenic Cells
Current Medicinal Chemistry Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Quantitative Coronary Angiography: Back to the Past
Recent Patents on Medical Imaging Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design